Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the recent launch of the Vericheck ddPCRâ„¢ Replication ...
Diogenx SAS raised €27.5 million (US$30.4 million) in a series A round to move a novel therapy for type 1 diabetes into clinical development. The Marseille, France-based company is building on the ...
A new antiretroviral target has been identified that suppresses HIV-1 replication and selectively kills HIV-1-infected cells. HIV-1 is the most common type of HIV. When HIV-1 leaves infected cells, ...